Wall Street analyst estimates for Coherus Oncology, Inc. (CHRS): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.21 | ||
| 2026-08-05 | $-0.19 | $-0.25 | +24.0% |
| 2026-05-11 | $-0.25 | $-0.26 | +5.1% |
| 2026-03-09 | $-0.34 | $-0.36 | +4.2% |
| 2025-11-06 | $-0.33 | $-0.32 | -3.1% |
| 2025-08-07 | $-0.34 | $-0.31 | -9.7% |
| 2025-05-12 | $-0.35 | $-0.31 | -12.9% |
| 2025-03-10 | $-0.44 | $-0.10 | -340.0% |
Valuation Ratios
| Price / Book | 2.98 |
| EV / EBITDA | -1.12 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $190.1M | $1.6M | $1.6M | $356.1M | $475.8M | $326.6M | $211.0M | $257.2M | $267.0M | $42.2M |
| Cost of Revenue | $254.4M | $160.5M | $3.2M | $17.1M | $37.7M | $57.6M | $70.1M | $159.0M | $117.6M | $17.7M |
| Gross Profit | -$64.3M | -$159.0M | -$1.7M | $339.0M | $438.2M | $269.0M | $141.0M | $98.3M | $149.4M | $24.4M |
| Research & Development | $254.4M | $162.4M | $110.2M | $94.2M | $142.8M | $363.1M | $199.4M | $109.4M | $93.3M | $105.0M |
| Selling, General & Admin | $51.6M | $71.3M | $94.2M | $137.0M | $139.1M | $169.7M | $198.5M | $185.6M | $150.4M | $99.0M |
| Operating Expenses | $306.0M | $233.7M | $204.4M | $231.2M | $281.8M | $532.8M | $397.8M | $301.5M | $261.1M | $204.0M |
| Operating Income | -$115.9M | -$232.1M | -$204.4M | $107.8M | $156.3M | -$263.9M | -$256.9M | -$203.2M | -$111.7M | -$179.5M |
| EBITDA | -$116.8M | -$225.3M | -$204.4M | $111.0M | $161.8M | -$260.7M | -$255.6M | -$193.9M | $60.9M | -$170.2M |
| Interest Expense | $8.0M | $9.6M | $9.7M | $17.6M | $21.2M | $23.0M | $32.5M | $40.5M | $27.2M | $9.0M |
| Pre-tax Income | -$127.8M | -$238.3M | -$209.4M | $92.8M | $135.7M | -$287.1M | -$291.8M | -$238.3M | $28.5M | -$183.1M |
| Income Tax | $656000 | 0 | 0 | $2.9M | $3.5M | 0 | 0 | -$380000 | 0 | 0 |
| Net Income | -$127.3M | -$238.2M | -$209.3M | $89.8M | $132.2M | -$287.1M | -$291.8M | -$237.9M | $28.5M | -$170.3M |
| EPS | $-3.04 | $-4.48 | $-3.22 | $1.29 | $1.85 | $-3.81 | $-3.76 | $-2.53 | $0.25 | $-1.45 |
| EPS (Diluted) | $-3.04 | $-4.48 | $-3.22 | $1.23 | $1.62 | $-3.81 | $-3.76 | $-2.53 | $0.25 | $-1.45 |
| Shares Outstanding (Diluted) | $41.9M | $53.1M | $65.0M | $73.2M | $83.5M | $75.4M | $77.6M | $94.2M | $114.8M | $120.4M |
Price
| Price | $1.22 |
| Market Cap | $188M |
| Exchange | NASDAQ |
| Country | US |
Related companies: AVTX · CCCC · CDXS · IMDX · IVVD · OABI · PLX
Explore sector: Healthcare · Biotechnology
More sections of CHRS: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks